Common-Size Income Statement
Quarterly Data
Paying user area
Try for free
Cigna Group pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cigna Group for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Cigna Group, common-size consolidated income statement (quarterly data)
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Pharmacy revenues
- There is a clear upward trend in pharmacy revenues as a percentage of total revenues from external customers, increasing from 65.85% in Q1 2020 to 76.4% by Q4 2024. This suggests a growing reliance on pharmacy-related business over the observed period.
- Premiums
- Premiums as a percentage of revenues consistently declined from 28.44% in Q1 2020 to 17.6% in Q4 2024, reflecting a decreasing contribution of premium income to the overall revenue mix during the timeframe.
- Fees and other revenues
- Fees and other revenues have shown a slight increase overall, beginning at 5.71% in Q1 2020 and ending at around 6.01% in Q4 2024, indicating modest growth in this revenue category.
- Pharmacy and other service costs
- Costs associated with pharmacy and other services steadily increased in proportion to revenues, moving from -63.46% to about -74.99% between Q1 2020 and Q4 2024, reflecting rising expense pressures in this segment.
- Medical costs and other benefit expenses
- There is a decreasing trend in medical costs and other benefits, dropping from -21.83% in early 2020 to approximately -15.55% by late 2024, implying improved medical cost management or shifts in cost structure.
- Gross profit
- Gross profit margin has fluctuated but generally declined from 14.7% in Q1 2020 to 9.46% by Q4 2024, indicating compression in profitability at the gross level over time.
- Net investment income
- Net investment income relative to revenues shows variability with an overall downward trend, decreasing from 0.93% in Q1 2020 to 0.42% in Q4 2024, suggesting reduced returns on invested assets or lower investment yields.
- Selling, general and administrative expenses (SG&A)
- SG&A expenses as a percentage of revenues decreased significantly from -8.91% in Q1 2020 to around -5.91% by Q4 2024, reflecting improved cost control or operational efficiency gains in administrative functions.
- Amortization of acquired intangible assets
- The trend of amortization costs shows a steady decline from -1.31% to -0.65%, indicating either reduced amortization expenses or less reliance on acquired intangible assets contributing to costs.
- Income from operations
- Operating income as a proportion of revenues experienced volatility but declined overall from 5.41% at the start to 3.32% by the end of the period, suggesting challenges in maintaining operating earnings margins amid rising costs.
- Interest expense and other
- Interest and similar expenses decreased modestly, from -1.03% to -0.55% of revenues, indicating improved debt management or lower interest rates on outstanding obligations.
- Debt extinguishment costs
- This category shows sporadic costs early on but becomes negligible or absent after Q2 2021, indicating limited impact of debt extinguishment activities in recent periods.
- Gain (loss) on sale of businesses
- Gains or losses from business sales show large fluctuations with significant gains early in 2020 and again in 2021, followed by small losses and gains in later periods, suggesting occasional one-time adjustments affecting results.
- Net realized investment gains (losses)
- Net investment gains and losses have been inconsistent, with some quarters experiencing negative impacts, notably a sharp loss of -3.22% in Q1 2024, pointing to volatility in investment performance.
- Income before income taxes
- Pre-tax income shows high variability with a notable spike in Q4 2020 at 13.01%, but generally remains in the 3.0%-5.0% range, with a dip to low positive or near-zero levels in 2023-2024, indicating uneven earnings before tax trends.
- Income taxes
- Income tax expenses relative to revenues remained largely negative as expected, fluctuating considerably, including an unusual positive value of 1.81% in Q4 2022, indicating potential tax benefits or adjustments.
- Net income (loss)
- Net income margins showed a substantial peak of 10.02% in Q4 2020, declining and fluctuating around 2.0%-3.0% subsequently, with some quarters showing near breakeven or slight losses, notably in early 2024, reflecting earnings volatility.
- Noncontrolling interests in net income
- Amounts attributable to noncontrolling interests gradually increased in absolute negative terms from -0.02% to -0.17%, indicating growing minority interests or share of losses assigned externally.
- Shareholders' net income (loss)
- Shareholders’ net income mirrored overall net income trends, peaking around Q4 2020, declining through subsequent years, and showing increased volatility or occasional losses towards the end of the period, underscoring fluctuating profitability attributable to owners.